Natural Capsules to discuss Q4FY26 results on June 2

Natural Capsules Limited has scheduled a conference call with investors and analysts to discuss its audited financial results for the fourth quarter and financial year ended March 31, 2026. The meeting is set to take place on Tuesday, June 2, 2026, at 4:00 PM IST. The discussion will focus on the company's performance for Q4 and FY26, along with its business outlook. The company confirmed that no price sensitive information will be disclosed during the call.

The announcement was made pursuant to Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted to both BSE Limited and the National Stock Exchange of India Limited to ensure compliance with regulatory requirements.

Management Participants

The conference call will feature key members of the company's leadership team who will address queries regarding the financial results and future strategies.

Name	Position
Mr. Sunil Mundra	Managing Director
Mr. Raj Kishore Prasad	Chief Financial Officer

Investors interested in participating can join via the provided toll-free numbers. Registration for the event is available through a dedicated link to facilitate access. For further information, stakeholders may contact the Investor Relations Advisor at TIL Advisors Private Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.19%	+5.34%	+2.53%	-8.06%	-20.29%	-34.83%

Natural Biogenex Private Limited, a material subsidiary of Natural Capsules Limited , has approved a rights issue to raise capital through the issuance of equity shares. The board of Natural Biogenex Private Limited sanctioned the issuance of 11,11,200 equity shares with a face value of ₹10 each for cash at par. The total issue size aggregates to ₹1,11,12,000.

The approval was granted during a board meeting held on May 27, 2026. The intimation regarding this decision was submitted under Regulation 30(9) of the SEBI (LODR) Regulations, 2015. The filing was made to BSE Limited and the National Stock Exchange of India Limited to inform the exchanges about the corporate action undertaken by the material subsidiary.

Rights Issue Details

The rights issue involves the following key parameters:

Particulars	Details
Total shares offered	11,11,200 Equity shares
Face value	₹10 per share
Issue price	₹10 (at par)
Total aggregate amount	₹1,11,12,000

The shares are being offered on a rights basis to eligible shareholders of the material subsidiary. The proceeds from the issue are intended to bolster the financial resources of Natural Biogenex Private Limited.